[US Stock Market Movements] Kodiak Sciences plummeted on October 14: sharp rebound followed by decline, high valuation, and financing risks

Interpretation of Kodiak Sciences' Sharp Drop on October 14

Keywords: Surge and pullback, overvaluation, financing risk

1. On September 28, 2026, the company announced that the primary endpoint of the DAYBREAK Phase III trial was met, leading to a significant soar in the stock price; as of October 8, the stock had seen a sharp short-term rise and a notable increase in valuation, putting pressure on profit-taking and valuation correction.

2. On September 30, 2026, the company had about $126 million in cash, with quarterly cash burn exceeding $60 million, still being in the pre-commercialization phase, and potential subsequent equity financing could lead to share dilution.

3. On September 28, 2026, although the company planned to submit a Zenkuda Biologics License Application, the product still needs to complete regulatory approval, and the timing of commercialization, pricing, and competitive landscape remain uncertain.

(Disclaimer: This content is generated by AI technology based on publicly available information for reference only and does not constitute investment advice.)